Cargando…
A randomized, double-blind comparison of OROS(® )hydromorphone and controlled-release morphine for the control of chronic cancer pain
BACKGROUND: Long-acting opioid formulations are advocated for maintaining pain control in chronic cancer pain. OROS(® )hydromorphone is a sustained-release formulation of hydromorphone that requires dosing once daily to maintain therapeutic concentrations. The objective of this study was to demonstr...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644667/ https://www.ncbi.nlm.nih.gov/pubmed/18976472 http://dx.doi.org/10.1186/1472-684X-7-17 |